Compass Therapeutics Statistics
Share Statistics
Compass Therapeutics has 137.59M shares outstanding. The number of shares has increased by 7.92% in one year.
| Shares Outstanding | 137.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 84.48M |
| Failed to Deliver (FTD) Shares | 4 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 2.10M, so 1.53% of the outstanding shares have been sold short.
| Short Interest | 2.10M |
| Short % of Shares Out | 1.53% |
| Short % of Float | 2.49% |
| Short Ratio (days to cover) | 4.14 |
Valuation Ratios
The PE ratio is -4.66 and the forward PE ratio is -3.51.
| PE Ratio | -4.66 |
| Forward PE | -3.51 |
| PS Ratio | 0 |
| Forward PS | 4.5 |
| PB Ratio | 1.33 |
| P/FCF Ratio | -4.88 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Compass Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.73, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.73 |
| Quick Ratio | 19.73 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.15 |
| Cash Flow / Debt | -23.44 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.29% and return on capital (ROIC) is -33.51%.
| Return on Equity (ROE) | -0.29% |
| Return on Assets (ROA) | -0.27% |
| Return on Capital (ROIC) | -33.51% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.33M |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 25.95% in the last 52 weeks. The beta is 0.75, so Compass Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.75 |
| 52-Week Price Change | 25.95% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.47 |
| Relative Strength Index (RSI) | 65.47 |
| Average Volume (20 Days) | 936.63K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.89M |
| Operating Income | -50.36M |
| Net Income | -42.49M |
| EBITDA | -48.47M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.33 |
Balance Sheet
The company has 24.23M in cash and 1.73M in debt, giving a net cash position of 22.50M.
| Cash & Cash Equivalents | 24.23M |
| Total Debt | 1.73M |
| Net Cash | 22.50M |
| Retained Earnings | -315.31M |
| Total Assets | 149.15M |
| Working Capital | 136.71M |
Cash Flow
In the last 12 months, operating cash flow was -40.62M and capital expenditures -30.00K, giving a free cash flow of -40.65M.
| Operating Cash Flow | -40.62M |
| Capital Expenditures | -30.00K |
| Free Cash Flow | -40.65M |
| FCF Per Share | -0.32 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CMPX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.58% |
| FCF Yield | -14.85% |
Analyst Forecast
The average price target for CMPX is $8, which is 302% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 302% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 8.59 |
| Piotroski F-Score | 3 |